HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

B30-MDP, a synthetic muramyl dipeptide derivative for tumour vaccination to enhance antitumour immunity and antimetastatic effect in mice.

Abstract
The effect of a muramyl dipeptide derivative (B30-MDP) on the augmentation of antitumour immunity against highly metastatic L5178Y-ML25 mouse lymphoma cells was examined in CDF1 (Balb/c x DBA/2) mice. Mice immunized with a mixture of X-irradiated tumour cells (10(3)) and B30-MDP (100 micrograms) on 7 days prior to challenge by viable tumour cells displayed a significant decrease in metastasis towards the target organs, liver and spleen, compared with that of untreated mice. Immunization of mice with the mixture on day 5 or 7 after tumour challenge, when the level of glutamic-pyruvic transaminase (GPT) and glutamic-oxaloacetic transaminase (GOT) in sera of mice inoculated with viable tumour cells was observed to be normal, caused less metastasis than immunization with X-irradiated tumour cells alone. Sensitization with X-irradiated tumour cells admixed with B30-MDP induced almost two times higher cytotoxicity of spleen cells against L5178Y-ML25 lymphoma cells than sensitization with X-irradiated tumour cells without B30-MDP. In contrast, cytotoxic activity of spleen cells against another target, L1210 lymphoma cells derived from BDF1 mice, was not observed by immunization with X-irradiated L5178Y-ML25 cells with or without B30-MDP. Specific lysis by splenic cells of the immunized mice against L5178Y-ML25 cells decreased to the normal level when T cells were deleted from the immunized spleen cells by the treatment of rabbit anti-mouse Thy1.2 antibody and rabbit complement. These results indicate that B30-MDP is able to augment a specific tumour immunity due to the enhancement of cytotoxicity mediated by T lymphocytes, and is useful as an immunopotentiating agent for active immunization of inactivated tumour cells.
AuthorsY C Yoo, I Saiki, K Sato, I Azuma
JournalVaccine (Vaccine) Vol. 10 Issue 11 Pg. 792-7 ( 1992) ISSN: 0264-410X [Print] Netherlands
PMID1441733 (Publication Type: Journal Article)
Chemical References
  • Adjuvants, Immunologic
  • Antineoplastic Agents
  • Vaccines, Synthetic
  • Acetylmuramyl-Alanyl-Isoglutamine
  • B 30-muramyl dipeptide
Topics
  • Acetylmuramyl-Alanyl-Isoglutamine (analogs & derivatives, immunology, pharmacology)
  • Adjuvants, Immunologic (pharmacology)
  • Animals
  • Antineoplastic Agents (immunology)
  • Cytotoxicity, Immunologic
  • Leukemia L5178 (immunology, prevention & control, therapy)
  • Liver Neoplasms, Experimental (immunology, secondary, therapy)
  • Lymphoma, T-Cell (immunology, prevention & control, therapy)
  • Mice
  • Neoplasm Metastasis (prevention & control)
  • Neoplasm Transplantation
  • Spleen
  • Tumor Cells, Cultured (radiation effects)
  • Vaccines, Synthetic (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: